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OBJECTIVEdDiabetes is associated with increased brachial and central blood pressure and
aortic stiffness.We examined the effect of intensivemultifactorial treatment in general practice on
indices of peripheral and central hemodynamics among patients with screen-detected diabetes.
RESEARCH DESIGN AND METHODSdAs part of a population-based screening and
intervention study in general practice, 1,533 Danes aged 40–69 years were clinically diagnosed
with screen-detected diabetes. General practitioners were randomized to provide intensive mul-
tifactorial treatment or routine care. After amean follow-up of 6.2 years, an unselected subsample
of 456 patients underwent central hemodynamic assessments by applanation tonometry. Central
pressure was derived from the radial pulse wave. Aortic stiffness was assessed as carotid-femoral
pulse wave velocity (aPWV). The intervention effect on each index of central hemodynamics was
analyzed by mixed-effects models adjusted for heart rate, cluster randomization, age, and sex.
RESULTSdAt screening, median age was 59.2 years (interquartile range 55.2–64.6); 289
patients (63%) were in the intensive treatment group, and 278 patients (61%) were men. Patients
in the intensive treatment group had a 0.51 m/s (95% CI20.96 to20.05, P = 0.03) lower aPWV
compared with routine care. Respective differences for central augmentation index (20.84%
[22.54 to 0.86]), pulse pressure (0.28 mmHg [21.75 to 2.32]), and systolic (21.42 mmHg
[24.47 to 1.64]) and diastolic (21.79 mmHg [23.72 to 0.14]) blood pressure were not statis-
tically signiﬁcant.
CONCLUSIONSdIntensive multifactorial treatment of screen-detected diabetes during
6 years in general practice has a signiﬁcant impact on aortic stiffness, whereas the effects on
other hemodynamic measures are smaller and not statistically signiﬁcant.
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Patients with clinically diagnosedtype 2 diabetes have a raised cardio-vascular risk proﬁle and often have
undiagnosed diabetes complications at the
time of diabetes diagnosis (1,2). The clear
beneﬁt of close individual cardiovascular
risk factor management in patients with
a new clinical diagnosis of type 2 diabetes
(3–5) has long driven calls for screening for
undiagnosed diabetes. However, until re-
cently the direct evidence needed to extend
these beneﬁts to thosewith screen-detected
diabetes was unavailable. The Anglo-
Danish-Dutch Study of Intensive Treat-
ment in People With Screen-Detected
Diabetes in Primary Care (ADDITION-
Europe trial) evaluated the effect of inten-
sive multifactorial treatment compared
with routine care of individuals with
screen-detected diabetes and found a non-
statistically signiﬁcant 17% risk reduction
of a composite cardiovascular end point (6).
Intervention studies with cardiovas-
cular events as outcome require very large
study samples or a long follow-up. Inter-
mediate end points that lie in the causal
pathway toward the clinically relevant
outcomes are consequently a useful tool
for assessing the effect of treatment in
clinical trials short of cardiovascular
events beyond a calculated cardiovascular
risk estimate. As reported in a recent review
andmeta-analysis (7), several studies in the
general population and in high-risk popu-
lations have shown that aortic stiffness,
measured by carotid-femoral pulse wave
velocity (aPWV), is a strong predictor of
cardiovascular disease (CVD) andmortality
independent of brachial blood pressure
and other cardiovascular risk factors. The
meta-analysis included studies with vari-
ous measurement methods of aPWV and
showed that each additional 1 m/s in
aPWV is associated with an increased
CVD risk in the range of 5–35% (7). Ac-
cordingly, aortic stiffness is increasingly
used as an intermediate end point in clini-
cal trials (8,9).
In short- and long-term clinical trials,
several classes of antihypertensive agents
have been shown to lower aortic stiffness
(8,10,11). Lipid-lowering treatment with
statins has shown to reduce aortic stiff-
ness in high-risk patients (9,12), and
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small clinical trials have indicated a ben-
eﬁcial effect of weight loss as well as exer-
cise training on aortic stiffness (13,14).
Only few studies have examined the asso-
ciation between glucose-lowering treat-
ment and aortic stiffness, and their results
are inconclusive (15,16). To our knowl-
edge, no studies have examined the effect
of multifactorial treatment of cardiovascu-
lar risk factors on aortic stiffness.
In clinical practice, cardiovascular
risk factors are usually treated simulta-
neously in diabetic patients, and before
implementing a screening program for
diabetes it is important to know whether
intensive multifactorial treatment of
screen-detected diabetes lowers the risk
of CVD. We examined the effect of inten-
sive multifactorial treatment compared
with routine care on the following central
hemodynamics: aortic stiffness, central
systolic and diastolic blood pressure,
pulse pressure, augmented pressure, and
augmentation index as intermediate car-
diovascular end points among individuals
with screen-detected diabetes in the Dan-
ish arm of the ADDITION-Europe trial.
RESEARCH DESIGN AND
METHODSdThe design and the ratio-
nale for the ADDITION-Europe study have
previously been reported (17,18). In brief,
the Danish arm of the ADDITION-Europe
study (ADDITION-Denmark) consisted of
two phases: 1) a screening phase and 2) a
pragmatic cluster-randomized parallel-
group trial. InﬁveDanish regions, 744 gen-
eral practices were invited to participate. Of
these, 190 agreed to participate and were
allocated to screening and randomized to
provide either routine care or intensive
multifactorial treatment of patients with
diabetes detected by screening.
Population
The screening phase took place in 2001–
2006 and consisted of a population-based
stepwise screening program to identify in-
dividuals with screen-detected diabetes.
It was conducted among the participating
general practitioners’ patients aged 40–69
years without known diabetes. The re-
cruitment and selection methods have
previously been described in detail
(19,20). In total, 1,533 individuals were
diagnosed with diabetes according to the
1999 World Health Organization criteria
(21) and were enrolled in the trial. In
2009, a follow-up examination was per-
formed. In two of ﬁve study centers (Hol-
stebroHospital and StenoDiabetes Center),
measurements of central hemodynamics
were carried out and successfully obtained
in 456 of 486 attending patients. These pa-
tients constitute our study sample. Of the
456 patients, 420 had measurements of
both aPWV and central blood pressure, 9
had measurements of aPWV only, and 27
had measurements of central blood pres-
sure only (Supplementary Fig. 1). The rea-
sons for missing measurements were as
follows: stationclosure owing to insufﬁcient
staff (n = 27), irregular pulse (aPWV, n = 4;
central blood pressure and augmentation
index, n = 12), and for aPWV, that the ca-
rotid or femoral artery pulse could not be
found (n = 26).
The study was approved by the local
ethics committee (Region Midt, Denmark)
and was conducted in accordance with
the 1996 Helsinki Declaration. Written in-
formed consent was obtained from each
patient at baseline and at follow-up.
Intervention
The speciﬁc characteristics of the inter-
ventions to promote intensive treatment
have previously been described in detail
(17). We aimed to educate and support
general practitioners and practice nurses
in target-drivenmanagement (usingmed-
ication and promotion of healthy lifestyle)
of hyperglycemia, hypertension, and
hypercholesterolemia based on the step-
wise regimen used in the Steno-2 study
(22,23). Treatment thresholds, targets,
and algorithms are provided in Supple-
mentary Table 1. Intensive treatment
was promoted through the addition of
several features to existing diabetes care.
Practice personnel were provided with
educational material for patients, and pa-
tients were sent reminders if annual
check-up appointments were overdue.
Practices received additional funding to
support the delivery of extra care added
to the usual care and consultations. Al-
though targets for treatment were speciﬁed
and classes of medication recommended,
decisions on prescriptions, including
choice of individual drugs, were made
by general practitioners and patients in
cooperation.
The general practitioners in the routine
care group were provided with diagnostic
test results only; their patients with screen-
detected diabetes received standard care of
diabetes according to the Danish national
guidelines (24).
Outcomes
In this secondary analysis, the outcomes
were central and peripheral hemodynam-
ics: aPWV, central systolic and diastolic
blood pressure, pulse pressure, augmented
pressure, augmentation index, brachial
systolic and diastolic blood pressure, and
brachial pulse pressure. The staff obtaining
the outcome measures was blinded for
randomization group.
Aortic pulse wave velocity. With the
patient in a supine position, brachial blood
pressure was measured after 10 min of rest
(Omron M6 comfort; Omron Healthcare,
Milton Keynes, U.K.). From the supine
systolic and diastolic blood pressure, mean
blood pressure was calculated (diastolic
blood pressure + 0.4 3 pulse pressure)
(25). The velocity of the pulse wave was
then assessed between the right carotid
and femoral sites by applanation tonometry
using the SphygmoCor device (version 8;
Atcor Medical) and a high-ﬁdelity tonom-
eter, which is a validated method of mea-
suring aPWV (26). The tonometer was
used to capture the wave forms at the ca-
rotid and subsequently at the femoral artery
simultaneously with an electrocardiogram
recording using the intersecting tangent
(27). The transit time was based on the
mean of 10 pulse waves. The distance
from the suprasternal notch to the carotid
artery was measured with a tape measure
and from the suprasternal notch to the fem-
oral artery with an anthropometer (seca;
Medical Scales and Measuring Systems,
Hamburg, Germany) to avoid overestima-
tion of the distance and subsequently the
velocity in obese individuals. The path
length was determined by subtracting the
carotid-sternal notch distance from the
femoral-sternal notch distance. In each pa-
tient, aPWVwas measured twice. If the dif-
ference of aPWV between the two
measurements was larger than 0.5 m/s, a
third measurement was taken. In the statis-
tical analysis, the average of the two closest
measurements in each patient was used.
Central blood pressure and augmenta-
tion index. With the patient in a supine
position, peripheral pressure waveforms
were recordedat the radial arteryusing appla-
nation tonometry (version 8, SphygmoCor
system; Atcor Medical). Based on a built-in
generalized transfer function using the
supine brachial systolic and diastolic blood
pressure for calibration, central waveforms
were calculated from the radial arterial
waveforms. From the central waveforms,
central systolic anddiastolic bloodpressure,
central pulse pressure, central augmented
pressure, and central augmentation index
were estimated. Central augmented pres-
sure was calculated as the contribution of
the pulse wave reﬂection to central systolic
pressure, and central augmentation index
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was calculated as the ratio between central
augmented pressure and central pulse pres-
sure.
Peripheral blood pressure. Brachial sys-
tolic and diastolic blood pressures were
measured three times after a 10-min rest
with an automated oscillometric blood
pressure recorder (Omron M6 comfort)
with the patient in a sitting position.
Brachial pulse pressure was calculated as
the difference between brachial systolic
and diastolic blood pressure. The average
of all three measurements for each pa-
rameter was used in the analysis.
Measurements at baseline and
at follow-up
Health assessments at baseline and at
follow-up were performed at the Danish
ADDITION study centers by trained staff
blinded for randomization group follow-
ing standard operating procedures (6).
Brieﬂy, height, weight, waist circumfer-
ence, and brachial blood pressure were
measured. In venous blood samples,
HbA1c, serum total cholesterol, serum
HDL cholesterol, serum triglycerides,
and plasma creatinine were measured.
Serum LDL cholesterol was calculated
using Friedewald equation (28). Urinary
albumin and urinary creatinine were
measured on spot urine. At baseline and
follow-up, self-report questionnaires were
used to collect information on ethnicity,
smoking status, alcohol consumption,
medication, and CVD (previous myocar-
dial infarction and stroke). Furthermore,
at follow-up we collected information
on self-reported episodes with angina
pectoris or arrhythmia and self-reported
cardiovascular revascularization.
Statistical analysis
Patient characteristics at baseline and at
follow-up are presented as means (SD)
or, in cases of skewed distributions, as
median (interquartile range [IQR]). For
proportions, exact CIs were calculated
(29).
The effect of intensive multifactorial
treatment on central hemodynamics was
analyzed by mixed-effects models with
adjustment for clustering (randomization
by general practice) and heart rate at time
of measurement, taking its direct func-
tional effect on the hemodynamic mark-
ers into account. The analysis of aPWV
was also adjusted for mean blood pres-
sure at time of measurement. In addition
to regression coefﬁcients, standardized
regression coefﬁcients (SD change in the
outcome) are presented.
Aortic stiffness is associated with the
intrasubject variation of the central hemo-
dynamic measurements (the higher the
level of stiffness, the larger the intrasubject
variation). To assure a full spectrum of
aortic stiffness, no measurements were
excluded in the primary analysis. For com-
parison, we subsequently performed a sub-
analysis, excluding measurements with
large intrasubject variation according to
the manufacturer’s guidelines (30,31). In
the subanalysis of aPWV, measurements
with a ratio .0.2 between aPWV SEM
and aPWV were excluded. For the meas-
urements of central blood pressure and
augmentation index, the software provides
an operator index based on the height of
the pulse waves, variations in the height
of the pulse waves, diastolic variation,
and deviation in the shape of the pulse
waves. In the subanalysis of central blood
pressure and augmentation index, mea-
surements with an operator index ,75
were excluded. A signiﬁcance level of
5% was used. Analyses were performed
using SAS version 9.2 (SAS Institute,
Cary, NC).
RESULTSdIn our study sample, 61%
of the patients were men, mean age was
59 years at screening, andmean follow-up
time was 6.2 years. At screening, modiﬁ-
able cardiovascular risk factors were ele-
vated (Table 1). Furthermore, 38% of the
patients were treated with antihyperten-
sive drugs, and lipid-lowering treatment
was used by only 10% in the routine care
group and by 12% in the intensive treat-
ment group. During follow-up, HbA1c,
total cholesterol, LDL cholesterol, trigly-
cerides, creatinine, and the proportion of
smokers decreased in both treatment
arms, whereas waist circumference, BMI,
and HDL cholesterol did not change
(Table 2). At follow-up, the medication
use was more or less similar between
treatment groups. Only ACE inhibitor or
angiotensin receptor blocker (ARB), aspi-
rin, overall glucose-lowering drugs, and
other glucose-lowering drugs, which
mainly accounted for repaglinide, were
more frequently used by the intensive
treatment group.
At follow-up, mean aPWV was 9.8
(SD 2.2) m/s in the routine care group and
9.4 (2.1) m/s in the intensive treatment
group (Table 2). With the cluster ran-
domization and heart rate at time of mea-
surement taken into account, aPWV was
0.51 m/s lower (95% CI20.96 to20.05;
P = 0.03) in the intensive treatment group
compared with routine care (Table 3).We
found no statistically signiﬁcant differen-
ces between treatment arms in brachial
systolic blood pressure, diastolic blood
pressure, or pulse pressure or central sys-
tolic blood pressure, diastolic blood pres-
sure, pulse pressure, augmented pressure,
or augmentation index.Whenwe excluded
aPWV measurements with large intrasub-
ject variation (72 out of a total of 1,140
measurements), 15 patients were excluded
from the analysis (2 from routine care and
13 from intensive treatment group), and
the difference in aPWV between treatment
arms was20.39 m/s (20.82 to 0.05). For
the analysis of central blood pressure and
augmentation index, excluding measure-
ments with an operator index ,75 (178
measurements of 1,046; 27 patients, 6
from routine care and 21 from intensive
treatment) did not change the results sub-
stantially.
Comparison of the intervention effect
on peripheral and central hemodynamics
in standardized analyses showed that the
largest intervention effect was on aPWV
(Fig. 1) and, subsequently, central dia-
stolic and systolic blood pressure. The ef-
fect on the peripheral hemodynamics was
further down the line or in the opposite
direction.
CONCLUSIONSdIn this secondary
analysis of a subset of 456 individuals
with screen-detected type 2 diabetes who
participated in the ADDITION-Denmark
trial, we found that individuals attending
practices randomized to provide intensive
treatment had lower aortic stiffness based
on aPWV after 6 years of follow-up
compared with those attending practices
randomized to provide routine care. Fur-
thermore, we found a statistically nonsig-
niﬁcant indication of lower central systolic
and diastolic blood pressure, augmented
pressure, and augmentation index in the
intensive treatment group.
Our results should be seen in the light
of the ﬁndings from the ADDITION-
Europe trial, which found a statistically
signiﬁcant difference in the cardiovascu-
lar risk factors between routine care and
intensive treatment: HbA1c, brachial
blood pressure, total cholesterol, LDL
cholesterol, and triglycerides and a statis-
tically nonsigniﬁcant 17% risk reduction
of a composite cardiovascular end point
after 5.3 years (6). In the ADDITION-
Europe trial, there was an indication
that the rate of cardiovascular events star-
ted to separate after 4 years of treatment.
Similar ﬁndings have been observed in
other trials of intensive treatment in
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patients with established type 2 diabetes
(5,22,32), indicating that in the presence
of a relatively low absolute event rate, the
effect of cardiovascular risk reduction
takes some time to translate into a lower
rate of hard events. Our ﬁndings lend
support to the notion that during the early
phases of cardiovascular risk lowering,
subclinical functional and/or structural
cardiovascular changes occur that under-
lie the later effect of treatment on hard
cardiovascular events. However, the oc-
currence of hard cardiovascular events
in this early time window may still
depend on the state of subclinical cardio-
vascular function and structure before the
start of treatment. Based on this effect-lag
concept and our results, it is possible that
the incidence curves in the ADDITION-
Europe trial will continue to separate as
cardiovascular events continue to accrue
in the posttrial follow-up. Results from
the Danish Steno-2 study (22) further
support this concept.
The level of cardiovascular risk factors
at follow-upwas similar between treatment
arms.Nonetheless, we found a difference in
aortic stiffness. Similarly, the Steno-2 study
also found a small or nonexistent difference
in several of the cardiovascular risk factors
after a mean follow-up of 7.8 years, and the
cardiovascular events were still reduced by
53% in the intensive treatment group (22).
Addressing several cardiovascular risk fac-
tors simultaneously, which is usually the
approach in general practice, therefore
seems to lower cardiovascular risk. Because
of the pragmatic study design and the treat-
ment strategy, which covered several treat-
ment components and features to provide
intensive treatment, we cannot conclude
on the impact of each single treatment
component; we can speculate on themech-
anisms involved only.
In our study, brachial systolic blood
pressure, central systolic blood pressure,
central pulse pressure, central augmented
pressure, and augmentation index were
not signiﬁcantly lower in the intensive
treatment group compared with the rou-
tine care group at follow-up. This is in
contrast to what we had expected, given
that the brachial blood pressure decreased
signiﬁcantly in the intensive treatment
group in the ADDITION-Europe trial.
Further, central aortic pressures and aug-
mentation index do not necessarily reﬂect
the same arterial wall properties as mea-
sured by aPWV. The velocity of the pulse
wave assessed at the carotid and femoral
artery is a direct measure of the elasticity of
the aorta, whereas augmented pressure,
augmentation index, central systolic blood
pressure, and pulse pressure are deter-
mined by the reﬂective properties of the
entire arterial tree, distance to the reﬂection
sites, the velocity of the forward and
reﬂected wave, and stroke volume (33).
The reﬂective properties of the arterial
wall can be modulated independently of
aortic stiffening (34,35) and vice versa
(11,36). In line with our study, Karalliedde
et al. (36) found a reduction only in aPWV
in diabetic patients treated with an ARB
over 24 weeks compared with a calcium
channel blocker, despite similar reductions
in augmentation index and brachial and
central pulse pressure. Moreover, Mitchell
et al. (11) found a reduced aPWV in indi-
viduals with stable coronary artery disease
treated with an ACE inhibitor for 4.5 years
compared with placebo and no difference
in augmentation index and brachial and
central pulse pressure between the two
groups. In our study, theﬁrst antihyperten-
sive drug of choice in the intensive treat-
ment group was ACE inhibitor, and at
follow-up, 72% of the intensive treatment
arm patients were treated with either an
ACE inhibitor or ARB compared with
62% in the routine care arm. This could
be the main reason for lower aPWV in the
intensive treatment group, as previous
studies have shown that blockade of the
renin-angiotensin system has a beneﬁcial
effect on the elastic properties of the arterial
wall (37).
In the analysis of aPWV, we also ad-
justed for mean blood pressure at time of
measurement to see whether the effect on
aPWV was driven by the effect on mean
blood pressure, and the effect was atten-
uated only modestly. Hence, the effect of
intensive multifactorial treatment is in-
dependent of the direct effect on blood
pressure, suggesting that the intervention
had a direct effect on the vessel wall.
The treatment algorithm in the in-
tensive treatment group included statins
to all patients and aspirin to patients
Table 1dBaseline characteristics of the study sample
N Routine (n = 167) Intensive (n = 289)
Age at diagnosis (years) 456 59.5 (54.2–65.2) 59.9 (55.7–64.2)
Women, % (95% CI) 456 43.7 (36.1–51.6) 36.3 (30.8–42.2)
White ethnic origin, % (95% CI) 456 98.2 (94.8–99.6) 94.1 (90.7–96.5)
Employed, % (95% CI) 456 45.5 (37.8–53.4) 40.5 (34.8–46.4)
Current smoker, % (95% CI) 456 33.5 (26.4–41.2) 31.1 (25.8–36.8)
Alcohol consumption (units per week) 407 10.5 (12.8) 10.8 (10.5)
BMI (kg/m2) 436 30.5 (5.7) 30.3 (5.0)
Waist circumference (cm)
Men 267 105.7 (13.7) 106.2 (11.9)
Women 168 99.3 (13.7) 98.7 (12.7)
Brachial systolic blood pressure (mmHg) 436 146.6 (18.8) 145.0 (18.5)
Brachial diastolic blood pressure (mmHg) 436 86.4 (11.0) 86.1 (10.0)
HbA1c (%) 436 6.4 (6.0–7.1) 6.4 (6.0–7.4)
Total cholesterol (mmol/L) 422 5.8 (1.2) 5.6 (1.1)
Triglycerides (mmol/L) 412 1.7 (1.1–2.4) 1.6 (1.2–2.2)
HDL cholesterol (mmol/L) 406 1.4 (0.3) 1.4 (0.4)
LDL cholesterol (mmol/L) 392 3.5 (1.0) 3.4 (1.0)
Plasma creatinine (mmol/L) 399 83.5 (75.0–96.0) 85.0 (76.0–95.0)
Albumin-to-creatinine ratio 425 0.5 (0.2–1.7) 0.6 (0.3–1.6)
History of myocardial infarction, % (95% CI) 442 3.8 (1.4–8.1) 4.2 (2.2–7.3)
History of stroke, % (95% CI) 425 1.3 (0.2–4.6) 0.4 (0.0–2.0)
Medication, % (95% CI)
Any antihypertensive drugs 440 38.8 (31.3–46.7) 37.8 (32.1–43.8)
ACE inhibitor or ARB 440 13.3 (8.5–19.5) 16.0 (11.9–20.9)
b-Blocker 440 17.0 (11.6–23.6) 17.8 (13.5–22.9)
Calcium channel blocker 440 10.3 (6.1–16.0) 6.2 (3.6–9.7)
Diuretic 440 20.6 (14.7–27.6) 21.8 (17.1–27.2)
Other antihypertensive drugs 440 0 (0–2.2) 1.1 (0.2–3.2)
Any glucose-lowering drug 440 0.6 (0.0–3.3) 0 (0–1.3)
Any lipid-lowering drug 440 9.7 (5.6–15.3) 12.4 (8.7–16.8)
Aspirin 440 6.1 (2.9–10.9) 11.6 (8.1–16.0)
Data are means (SD) or median (IQR) unless otherwise indicated. N, no. of observations.
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receiving antihypertensive medication. At
follow-up, 80% of patients in the in-
tensive treatment group were treated
with statins compared with 72% in the
routine care group, and aspirin was more
frequently used in the intensive treatment
group. The difference in statin treatment
could also explain part of the difference
in aortic stiffness at follow-up, as a few
studies have shown that statin treatment
lowers aortic stiffness (9,12), whereas the
destiffening effect of aspirin remains
speculative.
The most frequently used glucose-
lowering drug in our study was metfor-
min, which has a beneﬁcial effect on
cardiovascular risk (4). Nevertheless, a
meta-analysis has shown that metformin
does not reduce brachial systolic and dia-
stolic blood pressure (38). Few studies have
examined the effect of glucose-lowering
treatment on aortic stiffness (15,39), and
studies conducted among individuals
with diabetes are sparse (15).
There was no difference in BMI or
waist circumference at follow-up be-
tween the treatment arms, and the pro-
portion of smokers decreased equally in
the treatment arms during follow-up. It is
therefore unlikely that the lifestyle com-
ponent of the intensive treatment inter-
vention led to the observed aortic
stiffness effects.
This study is the ﬁrst examining the
effect of intensive multifactorial treatment
on central hemodynamics among individ-
uals with screen-detected diabetes in gen-
eral practice. All patients were screened and
treated by their general practitioner, show-
ing that the screening strategy and inter-
vention are feasible in general practice.
During follow-up, the evidence-based
guidelines of diabetes care in Denmark
(24,40) changed toward the treatment tar-
gets in the intensive treatment arm, which
could have evened out the effect of inten-
sive treatment. Nevertheless, we found a
lower aortic stiffness in patients treated
intensively. This suggests either that the
cardiovascular risk factor levels differed
more markedly in the earliest years of the
trial and had an effect on aortic stiffness that
carried forward or that even relatively small
differences in cardiovascular risk factor lev-
els can impact aortic stiffness if consistent
over 6 years.
The main limitation of this secondary
trial analysis is that our central hemody-
namic outcomes were not prespeciﬁed
before initiation of the study. Statistically,
the addition of nine outcomes increases
the possibility of getting statistically signif-
icant results simply by chance. However,
the nine outcomes should not be regarded
as independent, as they are all expressions
of the functional and structural processes
underlying the prespeciﬁed outcome:
CVD. The number of patients in the in-
tensive treatment group was larger than in
the routine care group, even though there
were no differences in the number and
types of practices in the two groups. The
practices were randomized before screen-
ing and inclusion of patients, but it seems
that the intervention allocation enhanced
the focus on screening and thereby inclu-
sion of patients in the intensive treatment
practices. Still, the patients did not differ
between groups regarding cardiovascular
risk factors at baseline. Another limitation
is the lack of measurements of central
hemodynamics at baseline, but based on
Table 2dFollow-up characteristics of the study sample
N Routine care Intensive treatment
Follow-up time (years) 456 6.3 (0.8) 6.2 (1.2)
Current smoker, % (95% CI) 456 24 (17.7–31.2) 23.9 (19.1–29.2)
Alcohol consumption (units per week) 451 9.3 (11.0) 9.7 (10.9)
BMI (kg/m2) 456 30.5 (5.8) 30.1 (5.0)
Waist circumference (cm)
Men 278 106.1 (14.5) 107.7 (12.5)
Women 177 97.7 (12.9) 96.8 (12.2)
HbA1c (%) 454 6.4 (6.1–6.8) 6.2 (5.9–6.8)
Total cholesterol (mmol/L) 454 4.4 (0.9) 4.2 (1.0)
Triglycerides (mmol/L) 454 1.4 (1.1–2.1) 1.3 (0.9–2.0)
HDL cholesterol (mmol/L) 454 1.4 (0.4) 1.3 (0.4)
LDL cholesterol (mmol/L) 444 2.3 (0.7) 2.2 (0.9)
Creatinine (mmol/L) 454 72 (63–86) 74 (65–87)
Albumin-to-creatinine ratio 452 1.1 (0.8–2.5) 1.4 (0.8–2.7)
Brachial systolic blood pressure (mmHg) 456 135.3 (16.6) 135.8 (17.5)
Brachial diastolic blood pressure (mmHg) 456 84.6 (10.7) 84.7 (10.8)
Brachial pulse pressure (mmHg) 456 50.6 (10.7) 51.1 (11.3)
Heart rate (bpm) 456 70.7 (12.3) 72.2 (12.2)
Central systolic blood pressure (mmHg) 447 124.5 (15.6) 122.9 (16.0)
Central diastolic blood pressure (mmHg) 447 81.9 (10.7) 80.6 (9.5)
Central pulse pressure (mmHg) 447 43.7 (10.7) 43.4 (11.2)
Central augmented pressure (mmHg) 447 12.3 (6.0) 11.7 (6.5)
Central augmentation index (%) 447 27.8 (9.2) 26.2 (10.1)
Aortic pulse wave velocity (m/s) 429 9.8 (2.2) 9.4 (2.1)
History of angina pectoris, % (95% CI) 447 5.5 (2.6–10.2) 10.9 (7.5–15.1)
History of myocardial infarction, % (95% CI) 445 6.1 (3.0–11.0) 6.0 (3.6–9.5)
History of stroke, % (95% CI) 445 4.3 (1.7–8.6) 4.6 (2.5–7.8)
History of arrhythmia, % (95% CI) 445 9.8 (5.7–15.5) 14.9 (10.9–19.6)
History of CABG or PCI, % (95% CI) 451 7.9 (4.3–13.1) 8.7 (5.7–12.6)
Medication, % (95% CI)
Any antihypertensive drugs 446 77.3 (70.1–83.5) 81.3 (76.2–85.6)
ACE inhibitor or ARB 446 62.6 (54.7–70.0) 72.1 (66.5–77.2)
b-Blocker 446 24.5 (18.1–31.9) 23.3 (18.5–28.7)
Calcium channel blocker 446 22.1 (16.0–29.2) 23.7 (18.8–29.1)
Diuretic 446 42.9 (35.2–50.9) 46.3 (40.4–52.3)
Other antihypertensives 446 2.5 (0.7–6.2) 1.4 (0.4–3.6)
Any glucose-lowering drug 446 51.5 (43.6–59.4) 65.0 (59.1–70.6)
Metformin 446 42.9 (35.2–50.9) 49.8 (43.8–55.8)
Insulin 446 4.9 (2.1–9.4) 9.2 (6.1–13.2)
Sulphonylurea 446 17.8 (12.3–24.5) 16.6 (12.5–21.5)
Thiazolidinedione 446 1.2 (0.1–4.4) 0 (0–1.3)
Other glucose-lowering drugs 446 4.3 (1.7–8.6) 15.2 (11.2–19.9)
Any lipid-lowering drug 446 81 (74.1–86.7) 85.5 (80.9–89.4)
Statins 446 72.4 (64.9–79.1) 80.2 (75.1–84.7)
Aspirin 446 42.9 (35.2–50.9) 79.9 (74.7–84.4)
Data are means (SD) or median (IQR) unless otherwise indicated. N, number of observations. CABG, cor-
onary artery bypass grafting; PCI, percutaneous coronary intervention.
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the study design and similar levels of
cardiovascular risk factors, we believe it is
reasonable to assume that the level of aortic
stiffness and central blood pressure were
similar in both groups at baseline and,
consequently, that the observed differences
occurred during the study. Because of the
study design, the general practiceswere not
blinded to treatment allocation, but the re-
search personnel conducting the measure-
ments at follow-up were unaware of the
treatment allocation.
Several prospective observational
studies have shown that a lower level of
aortic stiffness is associated with a lower
cardiovascular risk, as reported in a recent
meta-analysis (7). With our results ex-
trapolated based on estimates from this
meta-analysis, which included studies
with various measures of aortic stiffness,
the difference of 0.51 m/s would corre-
spond with a relative CVD risk reduction
of 7% by intensive multifactorial treatment
compared with routine care. However,
we cannot conclude that reducing aortic
stiffness also reduces the incidence of car-
diovascular events, even though this hy-
pothesis might be plausible. To conﬁrm
this theory, we need to follow our popula-
tion for future cardiovascular events.
In this secondary analysis of 456
patients with screen-detected diabetes
in a cluster randomized trial, we found
that patients treated intensively by general
practitioners have a lower level of aPWV
than individuals receiving routine care after
6 years of treatment. This means that
screening for type 2 diabetes followed by
intensive multifactorial treatment in gen-
eral practice leads to lower aortic stiffness, a
key intermediate cardiovascular outcome,
during the time window when treatment
effects on hard cardiovascular outcomes
are not yet observable.
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Figure 1dThe effect of the intervention on the population SD change in the hemodynamic
marker. Gray, model 1: adjusted for clustering (general practice) and heart rate at time of
measurement; black, model 2: model 1 plus adjustment for age and sex.
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